171 related articles for article (PubMed ID: 8963976)
21. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy.
Buyse G; Verpoorten C; Vereecken R; Casaer P
Eur J Pediatr Surg; 1995 Dec; 5 Suppl 1():31-4. PubMed ID: 8770576
[TBL] [Abstract][Full Text] [Related]
22. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Goldenberg MM
Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
[TBL] [Abstract][Full Text] [Related]
23. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
24. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
[TBL] [Abstract][Full Text] [Related]
25. Treatment of overactive bladder with modified intravesical oxybutynin chloride.
Saito M; Tabuchi F; Otsubo K; Miyagawa I
Neurourol Urodyn; 2000; 19(6):683-8. PubMed ID: 11071699
[TBL] [Abstract][Full Text] [Related]
26. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
[TBL] [Abstract][Full Text] [Related]
27. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia.
O'Flynn KJ; Thomas DG
Br J Urol; 1993 Nov; 72(5 Pt 1):566-70. PubMed ID: 10071538
[TBL] [Abstract][Full Text] [Related]
28. [Intravesical oxybutynin hydrochloride in the treatment of urge incontinence in the elderly].
Mizunaga M; Miyata M; Kaneko S; Taniguchi N; Yachiku S; Chiba K; Osanai H; Fujisawa M
Nihon Hinyokika Gakkai Zasshi; 1996 Jun; 87(6):923-7. PubMed ID: 8753011
[TBL] [Abstract][Full Text] [Related]
29. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
[TBL] [Abstract][Full Text] [Related]
30. Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
Wada N; Shimizu T; Takai S; Shimizu N; Tyagi P; Kakizaki H; Yoshimura N
Neurourol Urodyn; 2017 Apr; 36(4):1039-1045. PubMed ID: 27367752
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
32. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
Amark P; Eksborg S; Juneskans O; Bussman G; Palm C
Br J Urol; 1998 Dec; 82(6):859-64. PubMed ID: 9883225
[TBL] [Abstract][Full Text] [Related]
34. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
Buyse G; Verpoorten C; Vereecken R; Casaer P
J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
[TBL] [Abstract][Full Text] [Related]
35. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.
Guerra LA; Moher D; Sampson M; Barrowman N; Pike J; Leonard M
J Urol; 2008 Sep; 180(3):1091-7. PubMed ID: 18639290
[TBL] [Abstract][Full Text] [Related]
36. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
Madersbacher H; Jilg G
Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
[TBL] [Abstract][Full Text] [Related]
37. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
[TBL] [Abstract][Full Text] [Related]
38. [Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial].
Goto M; Kato K; Kondo A; Otani T; Takita T; Kobayashi M
Hinyokika Kiyo; 1988 Mar; 34(3):541-50. PubMed ID: 3389295
[TBL] [Abstract][Full Text] [Related]
39. [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder].
Luque Mialdea R; Martín-Crespo R; Hernández E; Sánchez O; Cañizo A; Fernández A; Aparicio C; Blanco T; Cebrían J
Cir Pediatr; 2005 Jan; 18(1):3-7. PubMed ID: 15901100
[TBL] [Abstract][Full Text] [Related]
40. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
